Myriad Genetics Unveils 11 New Genetic Testing Studies at NSGC 2025 Conference

Reuters
2025/11/06
Myriad Genetics Unveils 11 New Genetic Testing Studies at NSGC 2025 Conference

Myriad Genetics Inc. has announced the presentation of 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the upcoming National Society of Genetic Counselors (NSGC) 44th Annual Conference. The studies will feature products including the MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen, and Foresight® Carrier Screen. The research will be presented through a series of poster sessions, with topics covering RNA analysis in hereditary cancer testing, advancements in prenatal screening, and professional development for genetic counselors. The results will be presented during the conference on November 7 and 8, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570231-en) on November 06, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10